1 Gut resident Escherichia coli profile predicts the eighteen-

2 month probability and antimicrobial susceptibility of urinary

3 tract infections.

4 Veronika Tchesnokova¹, Lydia Larson¹, Irina Basova¹, Yulia Sledneva¹, Debarati

5 Choudhury¹, Thalia Solyanik¹, Jennifer Heng¹, Teresa Cristina Bonilla¹, Isaac

6 Pasumansky¹, Victoria Bowers¹, Sophia Pham¹, Lawrence T. Madziwa^{2,3}, Erika

- 7 Holden^{2,3}, Sara Y. Tartof^{4,5}, James D. Ralston^{2,3} and Evgeni V. Sokurenko^{1*}
- ¹Department of Microbiology, University of Washington School of Medicine, 1705
- 9 NE Pacific St., Seattle, WA 98195, USA
- 10 ²Kaiser Permanente Washington, 2715 Naches Ave. SW, Renton, WA 98057, USA
- ³Kaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Suite
- 12 1600, Seattle, WA 98101-1466, USA
- 13 ⁴Kaiser Permanente Southern California, Department of Research & Evaluation,
- 14 Pasadena, 100 S Los Robles, Pasadena, CA 91101, USA
- ⁵Kaiser Permanente Bernard J. Tyson School of Medicine, Department of Health
 Systems Science, 100 S Los Robles, Pasadena, CA 91101, USA
- 17

18 * **Corresponding author:** Evgeni V. Sokurenko, evs@u.washington.edu

- 19 Short title: Gut E. coli Profile Predicts 18-Month UTI Probability &
- 20 Antimicrobial Susceptibility

21 Abstract

22	Background: Community-acquired UTI is the most common bacterial infection
23	managed in general medical practice that can lead to life-threatening outcomes.
24	While UTIs are primarily caused by <i>Escherichia coli</i> colonizing the patient's gut,
25	it is unclear whether the gut resident <i>E. coli</i> profiles can predict the person's
26	risks for UTI and optimal antimicrobial treatments. Thus, we conducted an
27	eighteen-month long community-based observational study of fecal E. coli
28	colonization and UTI in women aged 50 years and above.
29	Methods and Findings. We enrolled a total of 1,804 women distributed among
30	age groups 50-59 yo (437 participants), 60-69 yo (632), 70-79 yo (532), and
31	above 80 yo (203), lacking antibiotic prescriptions for at least one year. The
32	provided fecal samples were plated for the presence of <i>E. coli</i> and other
33	enterobacteria resistant to trimethoprim/sulfamethoxazole (TMP/STX),
34	ciprofloxacin (CIP) and 3 rd generation cephalosporins (3GC). <i>E. coli</i> was also
35	characterized as belonging to the pandemic multi-drug resistant clonal groups
36	ST131 (subclone H30) and ST1193. Following sample collection, the women
37	were monitored for 18 months for occurrence of UTI.

E. coli was cultured from 90.8% fecal samples, with 24.1% containing bacteria resistant to TMP/STX, 19.4% to CIP, and 7.9% to 3GC. In 62.5% samples, only all-susceptible *E. coli* were present. Overall, there were no age-related differences in resistance prevalence. However, while the total *E. coli* H30 and

ST1193 carriage rates were similar (4.3% and 4.2%, respectively), there was a
notable increase of H30 carriage with age (P = .001), while carriage decreased
with age for ST1193 (P = .057).

Within 18 months, 184 women (10.2%) experienced at least one episode of UTI
- 10.9% among the gut *E. coli* carriers and 3.0% among the non-carriers
(P=.0013). The UTI risk among carriers of *E. coli* H30 but not ST1193 was
significantly above average (24.3%, P = .0004). The UTI probability increased
with age, occurring in 6.4% of 50-59 yo and 19.7% of 80+ yo (P<.001), with the
latter group being especially at high risk for UTI, if they were colonized by *E. coli* H30 (40.0%, P<.001).

52 E. coli was identified in 88.1% of urine samples, with 16.1% resistant to 53 TMP/STX, 16.1% to CIP, 4.2% to 3GC and 73.1% to none of the antibiotics. Among tested urinary E. coli resistant to antibiotics, 86.1% matched the 54 55 resistance profile of *E. coli* in the fecal samples, with the clonotyping and whole 56 genome sequencing confirming the matching strains' identity. Positive predictive 57 value (PPV) of using gut resistance profiles to predict UTI pathogens' susceptibility to TMP/STX. CIP. 3GC and all three antibiotics were 98.4%. 58 59 98.3%, 96.6% and 95.3%, respectively. Corresponding negative predictive 60 values (NPV) were 63.0%, 54.8%, 44.4% and 75.8%, respectively. The AUC 61 ROC curve values for the accuracy of fecal diagnostic testing for the prediction 62 of UTI resistance ranged .86-.89. The fecal test-guided drug-bug mismatch rate

- 63 for empirical (pre-culture) prescription of TMP-SXT or CIP is reduced to $\leq 2\%$ in
- 64 89.6% of patients and 94.8% of patients with an optional 3GC prescription.
- 65 **Conclusion**. The resistance profile and clonal identity of gut colonizing *E. coli*,
- 66 along with the carrier's age, can inform personalized prediction of a patients'
- 67 UTI risk and the UTI pathogen's antibiotic susceptibility within an 18-month
- 68 period.

69 Introduction

70 The personalized or precision medicine approach is based on defining the 71 potential risks, expected outcomes, and optimal treatment of diseases based on 72 an individual's unique biomarkers, which are usually genetically determined but 73 can also depend on and behavioral factors [1]. The indigenous microbiota that 74 colonizes the gut, vaging or other body compartments is considered an integral component of the human organism, influencing various aspects of individuals' 75 76 health (for review see [2, 3]). At the same time, the resident microflora serves 77 as a major source of opportunistic bacterial pathogens for the host, including 78 those resistant to multiple antibiotics [4-6]. However, it remains unclear how the 79 identification of certain bacterial species and/or sub-species lineages in the 80 colonizing microbiota can predict the person's risks for developing specific 81 clinical infections or guide antibiotic treatment choices, especially in the era of 82 continuously increasing antimicrobial resistance.

83 Gut resident microbiota, Escherichia coli and other enterobacterial species in 84 particular, is the main reservoir for strains causing the most common bacterial 85 infection treated by general practitioners - community-acquired urinary tract 86 infections (UTIs) with the estimated total annual incidence rate of up to 7% the 87 USA and globally [7-10]. Postmenopausal women, typically aged 50 or older, 88 face a particularly high risk of developing severe and drug-resistant forms of 89 UTIs [11, 12]. While acute uncomplicated cystitis is the most common form of 90 UTI, its very high incidence places a substantial financial burden on the

healthcare system, especially if the initial treatment choice was not effective
[10, 13]. Also, more severe UTI forms such as recurrent cystitis, pyelonephritis,
or urosepsis (an estimated one-third of sepsis cases begin as UTIs) significantly
contribute to the overall costs associated with UTIs, particularly in elderly [10,
13, 14].

96 UTIs are almost exclusively treated with antibiotics, thus representing a primary 97 single reason for antibiotic use in humans [15]. However, antimicrobial 98 resistance has reached pandemic proportions in the last few decades, 99 contributing to increased mortality rates and healthcare costs (estimated at 100 approximately \$2,000 per ineffective prescription) [16-19]. Because determining 101 the resistance profiles of infecting bacteria takes 2-3 days, physicians must 102 resort to the empirical (pre-culture) choice of antibiotics. Typically, empirical 103 treatment is inherently imprecise as it is not informed by the specific resistance 104 profile of infecting bacteria but relies on general resistance patterns in the local 105 community [20]. For empiric treatment of uncomplicated UTI, the Infectious 106 Diseases Society of America (IDSA) recommends treatment with an antibiotic if 107 the local resistance prevalence in *E. coli* is no more than 20%, whereas for 108 pyelonephritis or other severe forms, the recommended resistance prevalence 109 should be <10% [20-22]. Unfortunately, the resistance to commonly used 110 antibiotics is now often well above 20% and the empiric guesswork results in the 111 prescription of ineffective antibiotics ('drug-bug mismatches') in 15-35% of 112 cases, leading to increased health care cost and overuse of last-line, broad-113 spectrum antimicrobials [16, 18, 19].

114 It has been well-established that extraintestinal pathogenic *E. coli* and other 115 enterobacteria causing UTIs derive from the gut, where they reside as part of 116 the commensal microbiota, typically existing as a consortium of multiple strains 117 (for review see [23]). These commensals include *E. coli* strains resistant to 118 antibiotics, and their presence in the gut may not be contingent upon antibiotic 119 use by the individual [24-28]. Among the antibiotic resistant *E. coli* causing 120 UTIs, strains of two multi-drug resistant clonal groups (genetic families) 121 dominate in the USA and globally – one is the sequence types ST131-H30R/Rx 122 (aka ST131 clade C1/C2; E. coli H30 for further) and ST1193 [24, 25, 27, 29-123 33]. Their rampant spread was noted in the first and second decades of this 124 century, respectively, with fluoroquinolone resistance being the signature of 125 both clonal groups. It has been hypothesized that the high prevalence and 126 global spread of E. coli H30 and ST1193 could be connected to their success as 127 gut colonizers [25, 34-36].

128 Multiple studies have estimated the risks of extraintestinal infections associated 129 with gut carriage of multi-drug resistant *E. coli*. Generally, these studies have 130 focused on the risks of bacteremia and included samples from hospital/ICU-131 admitted patients and/or those who underwent various organ transplant 132 procedures [37-40]. The correlation between gut carriage and consequent drug-133 resistant infections has been sufficiently strong to motivate studies on gut 134 decolonization of patients at risk, employing methods such as fecal microbiome 135 transplantation, probiotics, and/or phage therapies [37, 41-44]. To our 136 knowledge, however, there have been no observational prospective studies to

assess the value of characterizing gut-colonizing bacteria for predicting the
risks and guiding the antimicrobial treatment of such a vastly common antibiotictreated medical condition as UTI. Additionally, while it is well-known that certain
risk groups for UTI exist, such as patients with diabetes, postmenopausal
women or, the elderly [45-47], it is unclear to what extent the probability of UTI
in those groups are also defined by the species or clonal type of gut-colonizing
enterobacteria.

144 Here, we present the outcomes of an 18-month prospective observational study 145 on the risk for UTI women above 50 yo and the correlation between the clonal 146 and resistance profiles of *E. coli* in pre-collected fecal samples and those 147 isolated from the follow-up clinical urine samples. The study group included 148 1,804 women receiving out-patient care in the Kaiser Permanente system in 149 Washington State, USA (KPWA), serving mostly the metropolitan Seattle/Puget 150 Sound Area, who had not received any antibiotics for at least one year before 151 providing the fecal sample. We demonstrate that the UTI risk, while dependent 152 on age, varied considerably based on the clonal identity of gut-colonizing E. 153 *coli*. Additionally, determining the resistance profile of gut *E. coli* significantly 154 improves the accuracy of resistance prediction for UTI-causing strains against 155 three commonly used antibiotics: trimethoprim/sulfamethoxazole (TMP/STX), 156 ciprofloxacin (CIP), and 3rd generation cephalosporins (3GC). Thus, we believe 157 that the analysis of gut microbiota for the presence, resistance profile, and 158 clonal identity of resident *E. coli* shows potential for a personalized medicine 159 approach in the clinical management of UTI, empowering antimicrobial

stewardship efforts and, potentially, developing effective means for infectionprevention.

162 Methods

163 Study design and participants. This prospective cohort study from May 1, 164 2021 through December 31, 2021 was conducted among women aged 50 years 165 and older enrolled in Kaiser Permanente Washington (KPWA). One-year 166 membership prior to enrollment was required to clinical and demographic data 167 prior to baseline. Besides enrollment, age and gender, exclusion criteria 168 included any antibiotic prescription, UTI and placement in a long-term care 169 facility within a year prior to enrollment in the study. This study was approved 170 by the KPWA) Research Institute Institutional Review Board. The procedural 171 details pertaining to the mailing of study kits to participants are described in the 172 previous manuscript [24].

173 Processing of fecal samples and typing of fecal E. coli was described in 174 detail previously [24]. Briefly, fecal samples were plated on either pre-poured 175 HardyCHROM[™] UTI agar plates (Hardy Diagnostic, USA) or plates prepared 176 from HiChromeTM UTI Agar (HiMedia Laboratories Pvt, Ltd.) supplemented with 177 ciprofloxacin (CIP. 0.5 mg/L), trimethoprim/sulfamethoxazole (TS, 4/76 mg/L). 178 ceftazidime (CAZ, 8 mg/L), ceftriaxone (CTX, 2 mg/L). Plates were incubated 179 16-20h at 37°C, and single colonies (SCs) morphologically identified as 180 potential *E. coli* were cultured, saved and tested further for (a) resistance to

181 CIP, TMP/STX and 3rd generation cephalosporins (3GC – CAZ and CTX), (b) 182 clonality based on sequencing of four loci – *fumC*, *fimH*, *gyrA* and *parC*, as 183 described previously [24].

Processing of clinical urine samples and typing of urine E. coli. If a study
participant submitted a urine sample to KPWA clinical laboratory, a routine
urinalysis test was performed, followed by culture and sensitivity testing if
required. Starting February 2022, the UW laboratory was provided an aliquot of
the urine sample, which was processed using the same protocol as fecal sample
described above, adding *E. coli* clonality where applicable to sample
information.

UTI identification. The incidence of urinary tract infections in study
participants was deduced from their electronic health records (EHRs).

following the submission of the fecal sample. UTI was characterized based
on the criteria outlined in Bruxvoort et al [7], including UTI diagnosis codes,
antibiotic prescriptions, urinalysis test results, and culture findings.

Records were examined once all participants had surpassed 18 months

197 Resistant E. coli isolates comparison using whole genome sequencing.

198 Whole genome sequencing was conducted using the Illumina MiSeq platform

199 following the manufacturer's guidelines. Genomic DNA libraries were

200 prepared using the Nextera XT Library Prep Kit (Illumina, CA). Raw data

201 were uploaded to the Enterobase database

193

202 (https://enterobase.warwick.ac.uk/) for genome assembly and allele calling

203 processes. Core gene sequences were utilized to assess the phylogenetic204 relationship among isolates within the same clones.

205 Search for sensitive E. coli clones within fecal samples. Fecal samples 206 were examined to identify the presence of the *E. coli* clone responsible for 207 UTI in the participant. Three methods were employed. Firstly, a minimum of 208 two individual single colonies were isolated directly from the sample during 209 initial processing. These colonies were then screened for resistance profiles 210 and clonal identity. If these isolated colonies did not match the 211 uropathogenic *E. coli* clone, further isolation and screening of 9-28 212 (averaging 13) individual colonies were conducted. Secondly, the 213 uropathogenic *E. coli* strains were subjected to testing for resistance against 214 a broader spectrum of antibiotics, including ampicillin (50 and 100 mg/L), 215 rifampin (2 and 4 mg/L), tetracycline (16 mg/L), cefazoline (4 and 8 mg/L), 216 chloramphenicol (16 and 32 mg/L), kanamycin (12.5 and 25 mg/L), 217 gentamicin (15 mg/L), spectinomycin (15 mg/L), streptomycin (50 mg/L), 218 trimethoprim (8 and 16 mg/L), and sulfamethoxazole (80 and 160 mg/L). 219 Subsequently, fecal samples were plated on the antibiotic of interest to 220 search for isolates exhibiting the same resistance profile. Thirdly, fecal 221 samples were resuspended in phosphate-buffered saline (PBS) and between 222 10³-10⁴ cfu/plate were cultured on McConkey agar. Plates were divided into sectors, and bacteria from each sector were collected and re-suspended in 1 223 224 mL PBS. A 100 uL aliquot of this suspension was used for DNA purification 225 using 5% Chelex 100 (Bio-Rad, Richmond, CA) [48]. The purified DNA was

then subjected to qPCR to detect the presence of urinary clone-specific loci
and/or SNPs. In the event of a positive reaction, the saved bacterial
suspension was plated again to obtain and test individual single colonies.

Whole genome sequencing. Matching sets of *E. coli isolates* from clinical
urine samples and predating fecal samples underwent sequencing on
Illumina MiSeq platform using MiSeq 600 cycle v3 kit (Illumina). Raw reads
were uploaded to Enterobase database (<u>https://enterobase.warwick.ac.uk/</u>)
where they were assembled. The core genes were then downloaded from
Enterobase and analyzed for sequence identity. The trees were bult using
MEGA v7 software. Enterobase uberstrain names are listed in Table S3.

Statistical analysis. Chi-square test was used to evaluate 2x2 comparisons.
Logistic regression was used to analyze the prevalence of different *E. coli*strains and the incidence of UTI among participants across different age
groups. The analysis was conducted using STATA 14.2 Software (StataCorp,
Texas, USA).

241 **Results**

242 Antibiotic resistant E. coli are carried at high rates by women without

recent exposure to antibiotics. We collected fecal samples from 1,804 women
of age 50 years or above who did not take antibiotics for at least one year prior
to enrollment. Among the enrollees, 437 women (24%) were of age 50-59, 632

(35%) aged 60-69, 532 (30%) aged 70-79 and 203 (11%) aged 80 and above
(Table 1) (Fig S1A).

248 As expected, *E. coli* was present in a vast majority of the fecal samples (90.8%) 249 on average) across all age groups, with a slight but statistically significant 250 decreased *E. coli* carriage observed for younger enrollees (Table 1) (Fig S1B). 251 The *E. coli* positive samples were tested for the presence of any resistance to 252 TMP/STX, CIP and 3GC. In 62.5% samples, all *E. coli* were sensitive to all three 253 antibiotics, 24.1% samples contained *E. coli* resistant to TMP/STX: 19.4% to 254 CIP and 7.9% to 3GC (Table 1), with 10.8% having *E. coli* resistant to more than 255 one antibiotic. There were no differences between the age groups in prevalence 256 of samples with resistant E. coli (Table 1) (Fig S1C-E).

257 Among the E. coli-positive fecal samples, clonal groups E. coli H30 and ST1193 258 were found among 4.3% and 4.2%, respectively, with a combined prevalence of 259 43.4% among the samples with CIP-resistant E. coli. The gut carriage of E. coli H30 significantly increased with age (P = .001), ranging from 2.3% in the 50-59 260 261 yo group to 7.9% in women of 80+ yo (Table 1) (Fig S1F), while an opposite 262 age-dependence tendency was observed for the carriage of ST1193, with 5.2% 263 in the youngest group but only 2.1% (P = .057) in the elder group (Table 1) (Fig. 264 S1G).

Thus, a third (34.1%) of women 50 yo and older without recent exposure to antibiotics carry gut *E. coli* that is resistant to at least one of the three commonly used antibiotics, with no overall differences in the resistant *E. coli* 268 carriage between different age groups. At the same time, the older women
269 tended to carry significantly more frequently *E. coli* from the multi-drug resistant
270 clonal group ST131-H30.

271 The 18-month probability of UTI occurrence depends on E. coli presence

and clonality. During the follow up 18 months of observation, 5-17 enrollees

per month were diagnosed with UTI (Fig S2), with a total 184 women (10.2%)

having at least one episode of UTI (Table 2). All urines were collected from

women as outpatients; thus, all UTI cases qualify as being community acquired.

276 The frequency of UTI cases significantly increased with age (Fig S1H),

277 occurring in 1 in 5 (19.7%) women of age 80+ (Table 2). Interestingly, across

the age groups UTI occurred nearly four-fold more frequently among women

who carried *E. coli* in the gut than in those with no *E. coli* presence in feces.

In the total cohort of enrollees, the 18-month rate of UTI did not significantly differ between the carriers of all-sensitive *E. coli* and those carrying *E. coli* resistant to any of the tested antibiotics (Table 2). In contrast, the rate of UTI was nearly significantly higher than average for the carriers of multi-drug resistant *E. coli* H30 (24.3%; p=.0004). Notably, the rate of UTI among the carriers of ST1193 was at the average level.

When analyzed by age groups, the rates of UTI increased with age among the carriers of all-sensitive, TMP/STX-resistant, and CIP-resistant *E. coli* but the increase with age did not reach the statistical difference across the 3GC carriers (Fig S1I-M). While the UTI rates did not change with age among the carriers of ST1193, the UTI rates increased with age among the *E. coli* H30
carriers, reaching the 18-month occurrence of 36.4% in women or age 70-79
and 40.0% of age 80+. Moreover, in the two elder groups of enrollees, the UTI
probability for the *E. coli* H30 carriers was significantly higher than for carriers
of any other *E. coli*.

Thus, nearly 1 in 8 of women aged 50 and above, who are not taking antibiotics but carry *E. coli* in their gut, would experience a UTI within an 18-month period. In the older women, however, the overall UTI frequency increases up to two-fold overall and nearly four-fold in those who are colonized with the multi-drug resistant *E. coli* H30.

300 E. coli is the predominant and most resistant urinary pathogen. To 301 evaluate the identity and resistance profiles of urinary pathogens we analyzed a 302 total of 134 bacteriology-positive urine samples submitted by our study 303 enrollees to the clinical laboratory as part of the initial UTI diagnostics. The 304 bacteriology-positive samples were evenly spread across the 18 months of 305 observation (Fig S2). E. coli was identified in 118 (88.1%) of the samples and 306 was predominant at a similarly high level across all ages. Out of the remaining 307 16 samples, more than half (9 samples) contained *Klebsiella* spp., with the rest 308 having Citrobacter spp. (in 2 samples), P. mirabilis (3), Salmonella enterica (1) 309 and E. faecalis (1). Among the urine-isolated E. coli, 82 (69.5%) isolates were 310 sensitive to all three antibiotics, 19 (16.1%) were resistant to TMP/STX, 19 311 (16.1%) to CIP and 5 (4.2%) to 3GC (Table 3), with 6 (4.6%) resistant to

multiple antibiotics (Table S1). Among the non- *E. coli* urinary pathogens, none
were resistant to any of the tested antibiotics, which is significantly lower
(p=.008) than the proportion of resistant *E. coli* among the clinical isolates
(Table S2).

Thus, in the community-acquired UTI among the women aged 50 and above, *E.* 317 *coli* is both the predominant pathogen and responsible for most of the antibiotic-318 resistant infections.

319 Resistance profile of E. coli in the urine samples match those in fecal 320 samples due to the strains' identity. Baseline fecal E. coli was available from 321 all 118 enrollees with *E. coli* positive UTIs. Among the fecal samples, 64.2% 322 contained all-sensitive gut E. coli, 20.3% contained E. coli resistant to 323 TMP/STX, 23.3% to CIP and 6.8% to 3GC. There was a highly significant (P < 324 .001) overlap between the presence of resistant E. coli in urine and the 325 corresponding fecal samples – out of 36 urine isolates resistant to any of the 326 three antibiotics, 31 (86.1%) had an *E. coli* with the same resistance pattern in 327 the corresponding fecal samples. Among them, 89.5% of urine isolates had an

E. coli with a matching resistance to either TMP/STX or FQ and 80% for the resistance to 3GC (Table 3). Similarly, in 83.7% cases when the urine *E. coli* was sensitive to all three antibiotics, there was no resistant *E. coli* in the corresponding fecal sample.

The high-level correspondence between the resistance phenotypes of fecal andurinary samples obtained within 18 months of each other suggests that the

same *E. coli* strain is present in both sample types. Indeed, in 21 cases when
both fecal and urine sample were available for genetic clonotyping and
contained isolates resistant to the same antibiotic(s), all of them were of the
same clonal sub-group (Table S1). We compared 9 pairs of such clonally
matching strains by whole genome sequencing and confirmed that the sameperson urine and fecal samples are much closer genetically to one another than
other strain pairs even of the same clonotype (Fig S3).

Five sample pairs with mismatched resistance profiles between fecal and UTI isolates were evenly spread across the 18 months of observation, obtained at months 4, 6, 13, 16 and 17 (Table S1). Out of those, 3 samples were available for the clonal identity, with all determined to be of a different nature.

Thus, there is a high correspondence between the resistance profiles of gut resident *E. coli* and UTI isolates obtained from the same person within 18 months from fecal sample.

348 Urinary E. coli prediction based on fecal E. coli antibiotic resistance

(FECAR) testing. Because only a small portion of *E. coli* from urine samples did
not have a fecal *E. coli* with a matching resistance profile, positive predictive
values (PPV) for the susceptibility to antibiotics ranged between 94.5% for the
all-sensitive urine isolates to 99.1% for those sensitive to 3GC (Table 4). The
negative predictive values (NPV; prediction of non-susceptibility) ranged
between 71.1% for any of the three antibiotics and 44.4% for 3GC. Notably,
PPV and NPV remained at similar levels for the resistance prediction for the

356 entire set of 134 urinary pathogens (i.e. including the 16 urine samples with 357 non- E. coli bacteria, all of which as indicated above, were sensitive to the three 358 antibiotics), because vast majority of the corresponding fecal samples had only 359 all-sensitive E. coli (Table 4; Table S2). We estimated the diagnostic value of a 360 potential fecal *E. coli* antibiotic resistance (FECAR) test to determine the 361 resistance of UTI-causing pathogens in our cohort. The values of AUC (Area 362 Under the Receiver Operating Characteristic (ROC) Curve) for the FECAR test 363 ranged from .86-.89, i.e., at the 'excellent' level [49].

364 We analyzed how, hypothetically, the FECAR testing could improve the 365 accuracy of empirical (pre-culture) treatment of the UTI cases in our study 366 population by guiding the antibiotics choice. Using FECAR testing, TMP/STX, 367 CIP and 3GC would be 'recommended' for use in nearly 78%, 76% and 93% of 368 all UTI cases, respectively, based on the absence of resistant E. coli in the 369 corresponding fecal samples (Table 5). The FECAR-guided antimicrobial choice would lead to a drug-bug mismatch in only 1.9%, 2.0% and 0.8% of cases, 370 371 respectively. Either TMP/STX or CIP would be recommended in almost 90% 372 case and at least one of the antibiotics in 95% cases (Table 5).

Based on the 2022 annual antibiogram of *E. coli* isolated in the clinical
microbiology laboratory of all KPWA enrollees, the local resistance to all three
antibiotics is ≤20% - 16.9% to TMP/STX, 12.8% to CIP, and 5.8% to 3GCR.
Thus, any of them can be recommended for the UTI treatment in our enrollees,
assuming all patients had an uncomplicated cystitis. In our cohort, however,

378 such FECAR-unguided treatment would lead to a drug-bug mismatch in 14.2% 379 for TMP/STX and CIP, which is significantly higher than the mismatch resulted 380 from the FECAR guidance (P = .0009 and P = .0011, respectively). For the 381 unguided 3GC treatment the mismatch would occur in 3.7% of cases, which is 382 not significantly higher (P = .0963).

383 In contrast, the use of TMP/STX, CIP and 3GC would be 'not recommended' by 384 FECAR in 21.6%, 23.9% and 6.8%, respectively, due to the presence of 385 resistant E. coli in feces. While in 41.4, 46.9 and 55.6%, respectively, of the 386 corresponding UTI cases, the isolate happened to be susceptible to the 387 antibiotic, the antibiotics use in the not recommended cases would result in 388 drug-bug mismatch rate that is significantly above the mismatch rates resulted 389 from the unguided treatment, well exceeding the 20% rates considered to be 390 acceptable by the IDSA recommendations.

391 **Discussion**

Our study demonstrates that the presence and clonal identity of gut *E. coli*contribute to the risk of UTI. Moreover, although the human gut is often
colonized by multiple strains of *E. coli* simultaneously (as discussed in detail
below), the presence/absence of gut *E. coli* resistant to commonly used
antibiotics could be used for predictive diagnostics of urinary pathogen
susceptibility, within 18 months of the fecal testing and with an 'excellent level'
of test accuracy. Thus, such testing can support a personalized medicine

approach to UTI management by improving prediction of UTI infection andtailoring the empiric treatment choice.

401 Although the time of reaching menopause varies widely, women aged 50 and 402 above are generally considered to be in the range of premenopausal to post-403 menopausal. Due to estrogen decline, a rise in vaginal pH, higher urine 404 retention in the bladder, and other factors, postmenopausal women are known 405 to be at an increased risk for severe, complicated, and drug-resistant forms of 406 UTI [50, 51]. All women selected for the study did not have exposure to 407 antibiotics and were not diagnosed with UTI or hospitalized for any reason at 408 least one year prior to the study enrollment. Although these criteria may result 409 in a study population with lower risk compared to a general population women 410 50 years and older, this would rather result in an underestimate of the potential 411 impact of FECAR, which could be expected to have an even higher impact in a 412 population with more frequent infection and therefore higher probability of 413 resistance.

As expected, *E. coli* was isolated from the fecal sample of most women. Though
a clear minority, *E. coli* non-carriers were ~2-times more common among
women younger than 70. This is a novel finding, the underlying reason for which
remains unclear. Also novel is the follow-up observation that *E. coli* non-carriers
are about three times less likely to have UTIs than carriers, strongly suggesting
that *E. coli* is the major causative species for UTI. These data provide further

support that the probability of UTI depends on and, thus, may be predicted by
the presence or absence of gut-colonizing *E. coli*.

422 We concentrated here on three antibiotics commonly used for the CA-UTI 423 treatment. TMP/SMX (Bactrim) is suggested as the first line antibiotic for 424 uncomplicated UTI, similar to nitrofurantoin or fosfomycin [52]. CIP is suggested 425 as an alternative drug of choice when the first line antibiotics cannot be used for 426 any reason, or as the first-choice antibiotic if pyelonephritis is suspected, 427 usually combined with a single-dose boost of parenteral 3GC. However, as 428 mentioned in the Introduction, the empirical use of antibiotics is recommended 429 for the treatment of cystitis only if the local resistance prevalence is below 20%. 430 or below 10% for the treatment of pyelonephritis [21].

Surprisingly, even though study participants did not take antibiotics for at least
a year prior enrollment, just over a third of them carried gut *E. coli* resistant to
one or more of the three antibiotics. Interestingly, the carriage of resistant *E. coli* did not differ significantly between age groups, in accordance with a lack of
evidence that increased age is a risk factor for carriage of drug-resistant
bacteria [28]. However, the lack of association could because our study enrolled
only women who had not taken antibiotics in the year prior.

The most striking difference between the age groups was found in the carriage
of *E. coli* belonging to the pandemic multi-drug resistant clonal groups *E. coli*H30 and ST1193. *E. coli* H30 is estimated to have emerged in the 1990s gained
notoriety as the main cause of antibiotic resistant UTIs globally since early

442 2000s [33, 53]. Independently of resistance, it is also associated with 443 complicated and severe forms of UTIs, such as recurrent cystitis, pyelonephritis, 444 urosepsis, and infections in diabetic and immunocompromised patients [54]. 445 ST1193 emerged later than E. coli H30 but started to challenge the latter in 446 global UTI predominance in the mid-late 2010s [29, 31]. It has been proposed 447 that the phenomenal global spread of both *E. coli* H30 and ST1193 is 448 associated with their success as gut colonizers, possibly connected to the 449 mutations responsible for CIP resistance [35, 36]. The fact that E. coli H30 is 450 significantly more commonly carried by older women corresponds to our 451 previous findings in a smaller prior study [11].

452 The underlying reason for the age differences in *E. coli* H30 and ST1193 453 carriage is not yet known. However, we believe that this observation suggests 454 that resistance *per se* might not be the main selective factor for gut colonization 455 and other host factors, e.g., immune status, may be in play. Whatever the 456 underlying reason for the different carriage rates it's important for predicting the 457 occurrence of UTI. The overall 18-month incidence of UTIs in E. coli H30 458 carriers was twice as high as the average – 1 in 5 women. This was due to an 459 astoundingly high rate of E. coli H30 UTIs in women aged 70+, occurring in 460 more than a third of the enrollees, higher than in almost every other category of 461 *E. coli* carriers of this age. Interestingly, the UTI rates for ST1193 carriers were 462 not different from the average, potentially reflecting differences either in the 463 urovirulence potential of the strains or in the host defense status of the 464 colonized populations.

465 The significantly higher rate of UTIs for *E. coli* H30 illustrates the importance of 466 predicting UTI based on the clonal identity of the resident strain, in combination 467 with considering host demographics. While we did not examine the UTI 468 incidence for other major clonal groups of *E. coli*, this finding highlights the 469 value of examining the microbiota composition beyond large taxonomic groups 470 or even species (as mostly done by microbiome studies) but at the sub-species, 471 clonal group level that we propose to term as a 'clonobiome' analysis [55]. As 472 with most human pathogens, the *E. coli* species is clonal by nature, with the 473 majority of strains belonging to a relatively limited number of genetically well-474 defined and closely related clonal groups (i.e., Sequence Types or STs) that 475 can significantly differ from each other in virulence potential and/or antimicrobial 476 resistance profiles [56, 57]. Thus, by defining the clonal diversity of the 477 colonizing strains, the clonobiome approach allows us to assess more 478 accurately the clinical risks and treatment options associated with the resident 479 microbiota. To note, it was shown that the clonal identity of multiple gut-480 colonizing *E. coli* strains can be directly determined in fecal samples by deep 481 sequencing of just two genetic loci – fumC and fimH (CH typing) [55].

While predicting the probability of UTI in certain risk groups could be of practical interest, we believe that, if a clinical infection develops, it is even more important to accurately predict the antibiotic susceptibility of the pathogen. We demonstrate here that, within up to 18 months of fecal sample analysis, the resistance of the gut resident *E. coli* – dubbed here as FECAR test - served as a valuable predictive tool for estimating the susceptibility of the UTI-causing 488 bacteria for the three tested antibiotics. Though this conclusion is based on the 489 limited testing and data we have for our population in the study, the significant 490 improvement in the potential antibiotic choice is reflected by the 'excellent' 491 discrimination level of FECAR for the resistance to TMP/STX, CIP and 3GC 492 based on the AUC values between 0.8 and 0.9 [49]. Due to the relatively low 493 overall resistance to third-generation cephalosporins (3GC), the reduction in 494 drug-bug mismatch rates in the allowed cases was not as obvious as with 495 TMP/STX and CIP, but the AUC value was also at the excellent level. Moreover, 496 because E. coli was responsible for nearly 90% of CA-UTI cases, the diagnostic 497 prediction was also excellent for all UTI cases overall. Thus, the accuracy of 498 predicting resistance profiles of UTI-causing *E. coli* based on the fecal sample 499 collected within 18 months is sufficiently high to warrant further studies to 500 develop this approach as a predictive tool for antibiotic selection in UTI. The 501 FECAR-guided empirical choice of antibiotics could lead to a several-fold 502 reduction of the drug-bug mismatches relatively to the unguided treatment.

503 Naturally, the correlation between the resistance profiles of gut E. coli and that 504 of urine E. coli suggests that the strains causing UTIs derived from the gut 505 colonizers. Indeed, clonal identity was established between the vast majority of 506 fecal and urine strains with matching resistance profiles when they were 507 obtained from the same individual. In our study, strain clonality was determined 508 by a highly discriminatory sub-ST genotyping method [58, 59], strongly implying 509 the identity of the strains that was confirmed by whole genome sequencing of 510 representative strain pairs.

511 Previous studies varied significantly in their estimates of the duration of gut 512 colonization by specific *E. coli* strains – ranging from several days to a few 513 years, with a possible existence of 'transient' colonizers with a short-lived gut 514 residence span and long-term 'resident' colonizers with a much slower turnover 515 [60]. Though our study did not analyze the duration of gut colonization per se, it 516 suggests that uropathogenic antibiotic-resistant strains can reside in the gut for 517 a relatively long time, making the 18-month predictability of the urinary 518 pathogen feasible. This corresponds to previous studies suggesting that E. coli 519 H30 and ST1193 strains may be well-adapted as colonizers [12, 34, 35, 61]. 520 Moreover, it has been proposed that the genetic factors contributing to gut 521 colonization could serve as evolutionary pre-adapted (coincidental) urovirulence 522 factors [62, 63]. Finally, our results support the hypotheses that persistent gut 523 colonization by antibiotic-resistant *E. coli* may not necessarily depend on an 524 antibiotic use by the host [26].

525 The human gut is usually colonized by multiple strains of *E. coli* simultaneously. 526 For example, it has been shown that *E. coli* H30 in the gut is found, on average, 527 with 1-2 other strains, often exhibiting different resistance profiles and in 528 different relative proportions. While in the current study, the genetic diversity of 529 gut resident *E. coli* was not analyzed, colonization by multiple strains is 530 expected for most enrollees. For example, the fact that in certain carriers of 531 resistant strains, UTIs were caused by sensitive strains could be due, at least in 532 some cases, to the possibility that resistant strains were co-colonizing the gut 533 with a sensitive strain that eventually caused the infection. Alternatively, this

could have happened because the resistant strain found originally in the fecal
sample was replaced by the sensitive strain as part of the strains' turnover. Gut
strains dynamics could also explain the fact that, in a small number of cases,
UTI was caused by a resistant strain not found in the fecal sample, which could
be acquired by the host after the original sample collection. This, however,
should be resolved in future studies.

540 It remains to be determined whether a more detailed exploration of gut E. coli 541 strains' diversity, fecal abundance, the presence/absence of putative virulence 542 factors, and different resistance genes could further improve the prediction of 543 the UTI risks and optimal treatment. In addition to validating our results, future 544 studies should also assess whether FECAR could be used for prediction of the 545 UTI pathogens resistance to a broader spectrum of antibiotics. Furthermore, the 546 strain-dependent UTI risks need to be delineated across various age groups and 547 genders, considering additional host factors such as co-morbidities,

548 immunodeficiency status, etc. Despite the limitations of our study and remaining 549 questions, we strongly believe that discerning gut *E. coli* profiles should become 550 an integral component of the personalized medicine approach in UTI 551 management. Additionally, our findings should prompt further research in the 552 development of innovative strategies to prevent UTIs by, for example, 553 selectively decolonizing gut carriers of highly urovirulent and/or multi-drug 554 resistant enterobacterial strains. This may not only diminish risks for severe 555 complications in the most vulnerable individuals but also contributes to curbing

- 556 the antimicrobial resistance pandemic by reducing the transmission and
- 557 community circulation of these pathogens.

558 Acknowledgments

- 559 This work was supported by the National Institutes of Health R01AI106007 and
- 560 R01AI150152 to EVS.

561 **References**

- 562 1. NIH. PERSONALIZED MEDICINE. Available at:
- 563 <u>https://www.genome.gov/genetics-glossary/Personalized-Medicine</u>.
 564 Accessed 2/23/2024.
- 565 2. Clemente JC, Ursell LK, Parfrey LW, Knight R. The impact of the gut
 566 microbiota on human health: an integrative view. Cell **2012**; 148(6):
 567 1258-70.
- Wilson M. The Human Microbiota in Health and Disease: An Ecological
 and Community-based Approach. 1st Edition ed. New York: Taylor &
 Francis group, 2018.
- 571 4. Donskey CJ. The role of the intestinal tract as a reservoir and source
 572 for transmission of nosocomial pathogens. Clin Infect Dis 2004; 39(2):
 573 219-26.

574	5.	Johnson JR, Russo TA. Extraintestinal pathogenic Escherichia coli:
575		"the other bad E coli". J Lab Clin Med 2002 ; 139(3): 155-62.
576	6.	Lamberte LE, van Schaik W. Antibiotic resistance in the commensal
577		human gut microbiota. Curr Opin Microbiol 2022 ; 68: 102150.
578	7.	Bruxvoort KJ, Bider-Canfield Z, Casey JA, et al. Outpatient Urinary
579		Tract Infections in an Era of Virtual Healthcare: Trends From 2008 to
580		2017. Clin Infect Dis 2020 ; 71(1): 100-8.
581	8.	Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol
582		2010 ; 7(12): 653-60.
583	9.	Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention,
584		and treatment of catheter-associated urinary tract infection in adults:
585		2009 International Clinical Practice Guidelines from the Infectious
586		Diseases Society of America. Clin Infect Dis 2010 ; 50(5): 625-63.
587	10.	Yang X, Chen H, Zheng Y, Qu S, Wang H, Yi F. Disease burden and
588		long-term trends of urinary tract infections: A worldwide report. Front
589		Public Health 2022 ; 10: 888205.
590	11.	Tchesnokova V, Riddell K, Scholes D, Johnson JR, Sokurenko EV. The
591		Uropathogenic Escherichia coli Subclone Sequence Type 131-H30 Is
592		Responsible for Most Antibiotic Prescription Errors at an Urgent Care
593		Clinic. Clin Infect Dis 2019; 68(5): 781-7.

594	12.	Tchesnokova VL, Rechkina E, Larson L, et al. Rapid and Extensive
595		Expansion in the United States of a New Multidrug-resistant
596		Escherichia coli Clonal Group, Sequence Type 1193. Clin Infect Dis
597		2019 ; 68(2): 334-7.
598	13.	Foxman B, Barlow R, D'Arcy H, Gillespie B, Sobel JD. Urinary tract
599		infection: self-reported incidence and associated costs. Ann Epidemiol
600		2000 ; 10(8): 509-15.
601	14.	Saint S. Clinical and economic consequences of nosocomial catheter-
602		related bacteriuria. Am J Infect Control 2000 ; 28(1): 68-75.
603	15.	Shapiro DJ, Hicks LA, Pavia AT, Hersh AL. Antibiotic prescribing for
604		adults in ambulatory care in the USA, 2007-09. J Antimicrob
605		Chemother 2014 ; 69(1): 234-40.
606	16.	Dellit TH, Owens RC, McGowan JE, Jr., et al. Infectious Diseases
607		Society of America and the Society for Healthcare Epidemiology of
608		America guidelines for developing an institutional program to enhance
609		antimicrobial stewardship. Clin Infect Dis 2007; 44(2): 159-77.
610	17.	Jenkins SG, Schuetz AN. Current concepts in laboratory testing to
611		guide antimicrobial therapy. Mayo Clin Proc 2012; 87(3): 290-308.

612	18.	Thorpe KE, Joski P, Johnston KJ. Antibiotic-Resistant Infection
613		Treatment Costs Have Doubled Since 2002, Now Exceeding \$2 Billion
614		Annually. Health Aff (Millwood) 2018 ; 37(4): 662-9.
615	19.	Moon RC, Marijam A, Mitrani-Gold FS, et al. Treatment patterns,
616		healthcare resource use, and costs associated with uncomplicated
617		urinary tract infection among female patients in the United States.
618		PLoS One 2022 ; 17(11): e0277713.
619	20.	Gupta K, Hooton TM, Naber KG, et al. International clinical practice
620		guidelines for the treatment of acute uncomplicated cystitis and
621		pyelonephritis in women: A 2010 update by the Infectious Diseases
622		Society of America and the European Society for Microbiology and
623		Infectious Diseases. Clin Infect Dis 2011; 52(5): e103-20.
624	21.	IDSA. Combating Antimicrobial Resistance: Policy Recommendations
625		to Save Lives. Clin Infect Dis 2011; 52(Suppl 5): S397-S428.
626	22.	Gupta K, Grigoryan L, Trautner B. Urinary Tract Infection. Ann Intern
627		Med 2017 ; 167(7): ITC49-ITC64.
628	23.	Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract
629		infections: epidemiology, mechanisms of infection and treatment
630		options. Nat Rev Microbiol 2015 ; 13(5): 269-84.

631	24.	Tchesnokova V, Larson L, Basova I, et al. Increase in the community
632		circulation of ciprofloxacin-resistant Escherichia coli despite reduction
633		in antibiotic prescriptions. Commun Med (Lond) 2023 ; 3(1): 110.
634	25.	Tchesnokova VL, Rechkina E, Chan D, et al. Pandemic Uropathogenic
635		Fluoroquinolone-resistant Escherichia coli Have Enhanced Ability to
636		Persist in the Gut and Cause Bacteriuria in Healthy Women. Clin Infect
637		Dis 2020 ; 70(5): 937-9.
638	26.	Lehtinen S, Blanquart F, Croucher NJ, Turner P, Lipsitch M, Fraser C.
639		Evolution of antibiotic resistance is linked to any genetic mechanism
640		affecting bacterial duration of carriage. Proc Natl Acad Sci U S A 2017;
641		114(5): 1075-80.
642	27.	Davies NG, Flasche S, Jit M, Atkins KE. Within-host dynamics shape
643		antibiotic resistance in commensal bacteria. Nat Ecol Evol 2019; 3(3):
644		440-9.
645	28.	Hu Y, Matsui Y, L WR. Risk factors for fecal carriage of drug-resistant
646		Escherichia coli: a systematic review and meta-analysis. Antimicrob
647		Resist Infect Control 2020; 9(1): 31.
648	29.	Tchesnokova V, Radey M, Chattopadhyay S, et al. Pandemic

649 fluoroquinolone resistant *Escherichia coli* clone ST1193 emerged via

650	simultaneous homologous recombinations in 11 gene loci. Proc Natl
651	Acad Sci U S A 2019 ; 116(29): 14740-8.

- 652 30. Pitout JD, DeVinney R. *Escherichia coli* ST131: a multidrug-resistant
 653 clone primed for global domination. F1000Res **2017**; 6.
- 654 31. Pitout JDD, Peirano G, Chen L, DeVinney R, Matsumura Y. *Escherichia*655 *coli* ST1193: Following in the Footsteps of *E. coli* ST131. Antimicrob
 656 Agents Chemother **2022**; 66(7): e0051122.
- 32. Johnson JR, Tchesnokova V, Johnston B, et al. Abrupt emergence of a
 single dominant multidrug-resistant strain of *Escherichia coli*. J Infect
 Dis **2013**; 207(6): 919-28.
- 660 33. Price LB, Johnson JR, Aziz M, et al. The epidemic of extended-
- 661 spectrum-beta-lactamase-producing *Escherichia coli* ST131 is driven
- by a single highly pathogenic subclone, *H*30-Rx. MBio **2013**; 4(6):
- 663 e00377-13.
- Sarkar S, Hutton ML, Vagenas D, et al. Intestinal Colonization Traits of
 Pandemic Multidrug-Resistant *Escherichia coli* ST131. J Infect Dis
 2018; 218(6): 979-90.
- 667 35. Fuzi M, Sokurenko E. Commensal Fitness Advantage May Contribute
 668 to the Global Dissemination of Multidrug-Resistant Lineages of
 669 Bacteria-The Case of Uropathogenic *E. coli*. Pathogens **2023**; 12(9).

670	36.	Marcusson LL, Frimodt-Moller N, Hughes D. Interplay in the selection
671		of fluoroquinolone resistance and bacterial fitness. PLoS Pathog 2009;
672		5(8): e1000541.

673 37. Campos-Madueno EI, Moradi M, Eddoubaji Y, et al. Intestinal

- 674 colonization with multidrug-resistant Enterobacterales: screening,
- 675 epidemiology, clinical impact, and strategies to decolonize carriers. Eur
- 676 J Clin Microbiol Infect Dis **2023**; 42(3): 229-54.
- 677 38. Denkel LA, Maechler F, Schwab F, et al. Infections caused by
- 678 extended-spectrum beta-lactamase-producing Enterobacterales after
- 679 rectal colonization with ESBL-producing *Escherichia coli* or *Klebsiella*

680 *pneumoniae*. Clin Microbiol Infect **2020**; 26(8): 1046-51.

- 681 39. Magruder M, Sholi AN, Gong C, et al. Gut uropathogen abundance is a
- risk factor for development of bacteriuria and urinary tract infection.
- 683 Nat Commun **2019**; 10(1): 5521.
- 684 40. Grasselli G, Scaravilli V, Alagna L, et al. Gastrointestinal colonization
- 685 with multidrug-resistant Gram-negative bacteria during extracorporeal
- 686 membrane oxygenation: effect on the risk of subsequent infections and
- 687 impact on patient outcome. Ann Intensive Care **2019**; 9(1): 141.

688	41.	Forsyth JH, Barron NL, Scott L, et al. Decolonizing drug-resistant E.
689		coli with phage and probiotics: breaking the frequency-dependent
690		dominance of residents. Microbiology (Reading) 2023; 169(7).
691	42.	Ghani R, Mullish BH, McDonald JAK, et al. Disease Prevention Not
692		Decolonization: A Model for Fecal Microbiota Transplantation in
693		Patients Colonized With Multidrug-resistant Organisms. Clin Infect Dis
694		2021 ; 72(8): 1444-7.
695	43.	Davido B, Salomon J, Lawrence C, et al. Impact of Fecal Microbiota
696		Transplantation for Decolonization of Multidrug-Resistant Organisms
697		May Vary According to Donor Microbiota. Clin Infect Dis 2018; 66(8):
698		1316-7.
699	44.	Dinh A, Duran C, Bouchand F, Salomon J, Davido B. Fecal Microbiota
700		Transplantation Is a New Effective Weapon to Fight Multidrug-
701		Resistant Bacteria, but Harmonization and More Data Are Needed. Clin
702		Infect Dis 2017 ; 65(8): 1425-6.
703	45.	Geerlings SE. Clinical Presentations and Epidemiology of Urinary Tract
704		Infections. Microbiol Spectr 2016; 4(5).
705	46.	Hooton TM. Clinical practice. Uncomplicated urinary tract infection. N
706		Engl J Med 2012 ; 366(11): 1028-37.

707	47.	Foxman B. Urinary tract infection syndromes: occurrence, recurrence,
708		bacteriology, risk factors, and disease burden. Infect Dis Clin North Am
709		2014 ; 28(1): 1-13.

Yang JL, Wang MS, Cheng AC, Pan KC, Li CF, Deng SX. A simple and
rapid method for extracting bacterial DNA from intestinal microflora for

ERIC-PCR detection. World J Gastroenterol 2008; 14(18): 2872-6.

713 49. Hosmer D, Lemeshow, S. Applied Logistic Regression, 2000.

50. Raz R, Gennesin Y, Wasser J, et al. Recurrent urinary tract infections

in postmenopausal women. Clin Infect Dis **2000**; 30(1): 152-6.

- 716 51. Hooton TM. Recurrent urinary tract infection in women. Int J Antimicrob
 717 Agents 2001; 17(4): 259-68.
- 718 52. Gupta K, Hooton TM, Roberts PL, Stamm WE. Patient-initiated

719 treatment of uncomplicated recurrent urinary tract infections in young

women. Ann Intern Med **2001**; 135(1): 9-16.

712

721 53. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, et al.

722 Intercontinental emergence of *Escherichia coli* clone O25:H4-ST131

producing CTX-M-15. J Antimicrob Chemother **2008**; 61(2): 273-81.

54. Johnson JR, Thuras P, Johnston BD, et al. The Pandemic H30

725 Subclone of *Escherichia coli* Sequence Type 131 Is Associated With

726	Persistent Infections and Adverse Outcomes Independent From Its
727	Multidrug Resistance and Associations With Compromised Hosts. Clin
728	Infect Dis 2016 ; 62(12): 1529-36.

- 55. Shevchenko SG, Radey M, Tchesnokova V, Kisiela D, Sokurenko EV. *Escherichia coli* Clonobiome: Assessing the Strain Diversity in Feces
 and Urine by Deep Amplicon Sequencing. Appl Environ Microbiol 2019;
 85(23).
- 733 56. Wirth T, Falush D, Lan R, et al. Sex and virulence in *Escherichia coli*:
 734 an evolutionary perspective. Mol Microbiol **2006**; 60(5): 1136-51.
- 735 57. Tchesnokova V, Billig M, Chattopadhyay S, et al. Predictive

736 diagnostics for *Escherichia coli* infections based on the clonal

association of antimicrobial resistance and clinical outcome. J Clin

- 738 Microbiol **2013**; 51(9): 2991-9.
- 739 58. Roer L, Johannesen TB, Hansen F, et al. CHTyper, a Web Tool for
 740 Subtyping of Extraintestinal Pathogenic *Escherichia coli* Based on the
- fumC and fimH Alleles. J Clin Microbiol **2018**; 56(4).
- 742 59. Weissman SJ, Johnson JR, Tchesnokova V, et al. High-resolution two743 locus clonal typing of extraintestinal pathogenic *Escherichia coli*. Appl
 744 Environ Microbiol **2012**; 78(5): 1353-60.

745	60.	Martinson JNV, Walk ST. Escherichia coli Residency in the Gut of
746		Healthy Human Adults. EcoSal Plus 2020 ; 9(1).
747	61.	Morales Barroso I, Lopez-Cerero L, Navarro MD, Gutierrez-Gutierrez B,
748		Pascual A, Rodriguez-Bano J. Intestinal colonization due to
749		Escherichia coli ST131: risk factors and prevalence. Antimicrob Resist
750		Infect Control 2018; 7: 135.
751	62.	Adiba S, Nizak C, van Baalen M, Denamur E, Depaulis F. From grazing
752		resistance to pathogenesis: the coincidental evolution of virulence
753		factors. PLoS One 2010 ; 5(8): e11882.
754	63.	Le Gall T, Clermont O, Gouriou S, et al. Extraintestinal virulence is a
755		coincidental by-product of commensalism in B2 phylogenetic group
756		Escherichia coli strains. Mol Biol Evol 2007; 24(11): 2373-84.

757

758 Table 1. Prevalence of different *E. coli* among women of different age

Characteristic ^a	Total	Age (yo)				P value ^b
	No. (%)	50-59	60-69	70-79	80+	_
		No. (%)	No. (%)	No. (%)	No. (%)	
Total	1804 (100)	437 (100)	632 (100)	532 (100)	203 (100)	
				002 (100)	,	
<i>E. coli</i> present	1638 (90.8)	388 (88.8)	561 (88.8)	500 (94)	189 (93.1)	.001
<i>E. coli</i> absent	166 (9.2)	49 (11.2)	71 (11.2)	32 (6)	14 (6.9)	
All-sensitive E. coli	1023 (62.5)	244 (62.9)	353 (62.9)	308 (61.6)	118 (62.4)	.583
3GC-R E coli	129 (7.9)	26 (6 7)	46 (8 2)	41 (8 2)	16 (8 5)	612
	123 (1.3)	20 (0.7)	40 (0.2)	τι (0.2)	10 (0.0)	. 012
TMP/STX-R <i>E. coli</i>	395 (24.1)	91 (23.5)	130 (23.2)	126 (25.2)	48 (25.4)	. 215

CIP-R <i>E. coli</i>		318 (19.4)	74 (19.1)	113 (20.1)	97 (19.4)	34 (18)	. 655
	H30	70 (4.3)	9 (2.3)	24 (4.3)	22 (4.4)	15 (7.9)	.001
	ST1193	68 (4.2)	20 (5.2)	25 (4.5)	19 (3.8)	4 (2.1)	.057
759							

^a Prevalence of any or no *E. coli* carrying samples was calculated as percent from total number of samples;
 prevalence of resistant *E. coli* carrying samples was calculated as percent of any *E. coli* carrying samples.

^b P values were derived from logistic regression using age in years as predictor and *E. coli* carriage as
 outcome, with sensitive/resistant *E. coli* carriage restricted for overall *E. coli* carriage in a sample; P < .05
 in bold.

765

Characteristic ^a	Total	P value		Age	e (yo)		P value ^f
	No. (%)		50-59	60-69	70-79	80+	
			No. (%)	No. (%)	No. (%)	No. (%)	
Total	184 (10.2)		28 (6.4)	51 (8.1)	65 (12.2)	40 (19.7)	<.001
<i>E. coli</i> present	179 (10.9)	. 0013 b	27 (7)	49 (8.7)	64 (12.8)	39 (20.6)	<.001
<i>E. coli</i> absent	5 (3.0)		1 (2)	2 (2.8)	1 (3.1)	1 (7.1)	.796
All-sensitive E. coli	121 (11.8)	.252 °	22 (9)	33 (9.3)	45 (14.6)	22 (18.6)	.001
3GC-R <i>E. coli</i>	12 (9.3)	.381 ^d	1 (3.8)	4 (8.7)	4 (9.8)	3 (18.8)	.218
TMP/STX-R <i>E. coli</i>	36 (9.1)	.131 ^d	5 (5.5)	9 (6.9)	10 (7.9)	12 (25)	.002

	CIP-R <i>E. coli</i>	43 (13.5)	.449 ^d	4 (5.4)	13 (11.5)	14 (14.4)	12 (35.3)	<.001
	H30	17 (24.3)	.0003 ^e	0 (0)	3 (12.5)	8 (36.4)	6 (40.0)	<.001
	ST1193	8 (11.8)	.821 ^e	2 (10)	4 (16)	2 (10.5)	0 (0)	.927
767	^a UTI rates are calcu	lated as perc	entage of p	atients who	had UTI from	n total numb	er of females	in this
768	group.							
769	^b P value calculated	in Chi-square	e test compa	aring UTI in	<i>E. coli</i> carrie	rs vs non-ca	rriers; P < .0	∍5 in bold.

^c P value calculated in Chi-square test comparing UTI in any resistant vs all sensitive *E. coli* carriers.

^d P value calculated in Chi-square test comparing UTI in carriers of *E. coli* resistant to particular group of
 antibiotics vs all sensitive *E. coli*.

* P value calculated in Chi-square test comparing UTI in H30 or ST1193 vs any other *E. coli* carriers; P <
.05 in bold.

- ^f P values calculated in logistic regression with age as a predictor, unconstrained or constrained by group
- 776 predictor; P < .05 in bold

777

778 Table 3. Coincidence of sensitive and resistant *E. coli* in clinical urine samples with identified

779 uropathogen (N = 134) and respective fecal samples.

UTI <i>E. coli</i> in Feca		Overlap	P value ^a	
	sample			
No. (%)		No. (% UTI)		
	No. (% UTI)			
134 (100)				
118 (88.1)	118 (100)	118 (100)	< .001	
82 (69.5)	73 (54.9)	69 (84.1)	< .001	
19 (16.1)	31 (23.3)	17 (89.5)	< .001	
19 (16.1)	27 (20.3)	17 (89.5)	< .001	
5 (4.2)	9 (6.8)	4 (80)	< .001	
	UTI No. (%) 134 (100) 118 (88.1) 82 (69.5) 19 (16.1) 19 (16.1) 5 (4.2)	UTI E. coli in Fecal sample No. (%) sample No. (%) No. (% UTI) 134 (100) 118 (100) 118 (88.1) 118 (100) 82 (69.5) 73 (54.9) 19 (16.1) 31 (23.3) 19 (16.1) 27 (20.3) 5 (4.2) 9 (6.8)	UTIE. coli in FecalOverlapsampleNo. (%)SampleNo. (%)No. (% UTI)134 (100)No. (% UTI)118 (88.1)118 (100)118 (88.1)118 (100)82 (69.5)73 (54.9)69 (84.1)19 (16.1)31 (23.3)17 (89.5)19 (16.1)27 (20.3)17 (89.5)5 (4.2)9 (6.8)4 (80)	

UTI caused by non- E. coli (% total)	16 (11.9)	15 (93.8)	N/A ^b	
All-sensitive non- <i>E. coli</i> (% of non- <i>E. coli</i> uropathogen)	16 (100)	12 (75)	12 (75)	< .001

781 ^a P value calculated in logistic regression of the outcome (uropathogen) from predictor (fecal *E. coli*)

782 ^b N/A, not applicable

780

 Table 4. Urinary *E. coli* prediction based on fecal *E. coli* sensitivity test results. 783

E. coli in sample	<i>E. coli</i> UTI (N = 118)			All known bug UTI (N = 134)			
	PPV, % [Cl95]	NPV, % [Cl95]	AUC ^a	PPV , % [Cl95]	NPV, % [Cl95]	AUC ^a	
All sensitive <i>E. coli</i>	94.5	71.1	0.8577	95.3	66.7	0.8577	
	[86.6, 98.5]	[55.7, 83.6]		[88.5, 98.7]	[51.6, 79.6]		
CIP-S E. coli	97.7	54.8	0.8767	98.0	53.1	0.8822	
	[91.9, 99.7]	[36.0, 72.7]		[93.1, 99.7]	[34.7, 70.9]		
TMP/STX-S E. coli	97.8	63.0	0.8894	98.1	58.6	0.8908	
	[92.3, 99.7]	[42.4, 80.6]		[93.2, 99.7]	[38.9, 76.5]		
3GC-S E. coli	99.1	44.4	0.8779	99.2	44.4	0.8806	

	[95.0, 100.0]	[13.7, 78.8]	[95.6, 100.0]	[13.7, 78.8]
784				

785 ^a AUC, Receiving Operator Curve analysis (ROC) Area Under Curve

786

787 Table 5. Predictive power of knowing fecal bacterial resistance for

788 treatment of UTI.

789

Antibiotic	Allowed		Resistance in		Resistance		P value
			allo	allowed		rall	
	No.	%	No.	%	No.	%	
TMP/STX	105	78.4	2	1.9	19	14.2	.0009
CIP	102	76.1	2	2.0	19	14.2	.0011
3GC	125	93.2	1	0.8	5	3.7	.0963
TMP/STX or CIP	120	89.6	N/A	N/A	N/A	N/A	N/A
TMP/STX or 3GC	127	94.8	N/A	N/A	N/A	N/A	N/A
CIP or 3GC	126	94.0	N/A	N/A	N/A	N/A	N/A
TMP/STX or CIP or 3GC	127	94.8	N/A	N/A	N/A	N/A	N/A

791 Supporting information

- 792 **S1 Fig.** Analysis of gut *E. coli* carriage and UTI incidence by age.
- 793 **S2 Fig**. UTI incidence rates and uropathogens characteristics.
- 794 **S3 Fig.** Phylogenetic relationship between fecal (F) and clinical urine (CU) E.
- *coli* belonging to the same clonal group but isolated from different patients.
- 796 **S1 Table**. UTI *E. coli* resistant to antibiotics.
- 797 S2 Table. Non- E. coli UTI uropathogens.
- 798 **S3 Table**. All data by enrollee.